循環器臨床サピア　8　心不全の急性期対応

出版社： 中山書店
著者：
発行日： 2010-06-04
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784521731681
シリーズ： 循環器臨床サピア
電子書籍版： 2010-06-04 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

本書は，急性心不全という概念ではなく，心不全の急性期対応を如何に行うかを主眼として編集されている．そのコンセプトは，症状を取るための急性期対応に加えて，その心臓が次に戻るべきレベルをいかに改善された高い状態にするかということである。循環器病にかかわるすべての医師にとっての，現時点における心不全治療の必携書である。

目次

  • 循環器臨床サピア　8　心不全の急性期対応

    ―目次―

    1章：心不全急性期の病態を知る
    　A．心不全とは何か
    　B．心不全をみつける
    　C．心不全急性期の古典的分類を見直す
    　D．心不全急性期の臨床病型に親しむ
    　　ML:右心不全と拡張不全の考え方
    　E．心不全急性期の病態を把握する
    　　1．血圧・脈拍測定で病態を把握する
    　　2．超音波検査で病態を知る
    　　3．スワンガンツカテーテルを使って病態を評価する
    　　ML:胸部X線写真を活用する
    　　ML:時間尿量測定の意義を知る
    　　ML:動脈血・静脈血酸素飽和度測定を役立てる

    2章：心不全急性期の治療薬を使いこなす
    　A．鎮静
    　B．利尿薬
    　C．硝酸薬
    　D．Ca拮抗薬
    　E．ジギタリス
    　F．β遮断薬
    　G．hANP
    　H．PDE阻害薬と類似薬
    　I．抗不整脈薬
    　J．ドパミン・ドブタミン
    　K．ノルエピネフリン
    　　ML:心不全急性期の病態と薬剤選択
    　　ML:心筋保護を考えた薬剤選択

    3章：心不全急性期の非薬物療法に親しむ
    　A．挿管・呼吸管理
    　B．ペースメーカ
    　C．ICD/CRT-D
    　D．IABP・PCPS
    　E．VAS
    　F．弁修復・置換術
    　G．心臓弁以外の緊急手術
    　H．心臓移植
    　I． 血液浄化

    4章：心不全の原因疾患と急性期対応を知る
    　A．急性心筋梗塞
    　B．陳旧性心筋梗塞
    　C．高血圧性心不全
    　D．（拡張型）心筋症
    　E．大動脈弁疾患
    　F．僧帽弁疾患
    　G．三尖弁疾患
    　H．徐脈性心不全
    　I．頻脈性心不全
    　　ML:急性心不全と慢性心不全の急性増悪

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 心不全急性期の病態を知る

P.6 掲載の参考文献
1) Cotter G, et al. The pathophysiology of acute heart failure. Is it all about fluid accumulation? Am Heart J 2008 ; 155 : 9-18.
PubMed
2) Cleland JGF, et al. The EuroHEart Failure survey program : A survey on the quality of care among patients with heart failure in Europe : Part 1 : Patients characteristics and diagnosis. Eur Heart J 2003 ; 24 : 442-463.
 
3) Benza RL, et al. Arrythmias in heart failure exacerbation : The OPTIME-CHF study. Circulation 2001 ; 104 : 525.
 
4) Lewin J, et al. Clinical deterioration in established heart failure : What is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail 2005 ; 7 : 953-957.
PubMed
5) Ljungman S, et al. Role of the kidney in congestive heart failure : Relationship of cardiac index to kidney function. Drugs 1990 ; 29 : 10-21.
 
6) Gherghiade M, et al. Congestion is an important diagnostic and therapeutic target in heart failure. Rev Cardiovasc Med 2007 ; 7 (Suppl) : S21-S241.
 
7) Gherghiade M, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006 ; 296 : 2217-2226.
 
8) Milo-Cotetr O, et al. Acute heart failure associated with high admission blood pressure. A distinct vascular disorder? Eur J Heart Fail 2007 ; 9 : 178-183.
 
9) Cotter G, et al. Fluid overload in acute heart failure. Redistribution and other mechanism beyond fluid accumulation. Eur J Heart Fail 2008 ; 10 : 165-169.
PubMed
10) Gandhi SK, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001 ; 344 : 17-22.
PubMed
11) Vlacholpolos C, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005 ; 112 : 2193-2220.
PubMed
12) Ilva T, et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail 2008 ; 10 : 772-779.
 
13) Nohria A, et al. Cardiorenal interactions : Insights from the ESCAPE trial. J Am Coll Cardiol 2008 ; 51 : 1268-1274.
 
14) Klein L, et al. Admission or changes in renal function during hospitalization for worsening heart failure : Results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). Circ Heart Fail 2008 ; 1 : 25-33.
 
15) Ahmed A, et al. Incident heart failure hospitalization and subsequent mortality in chronic heart failure : A propensity-matched study. J Card Fail 2008 ; 14 : 211-218.
PubMed
P.12 掲載の参考文献
1) Jourdain P, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure : The STARS-BNP Multicenter Study. J Am Coll Cardiol 2007 ; 49 (16) : 1733-1739.
PubMed
1) McKee PA, et al. The natural history of congestive heart failure : The Framingham study. N Engl J Med 1971 ; 285 (26) : 1441-1446.
PubMed
2) Costanzo MR, et al. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure : A propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J 2007 ; 154 : 267-277.
 
2) Maisel AS, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002 ; 347 (3) : 161-167.
PubMed
P.18 掲載の参考文献
1) Killip T, Kimball T. Treatment of myocardial infarction in a coronary care unit : A two year experience with 250 patients. Am J Cardiol 1967 ; 20 : 457-464.
 
2) Yano K, et al. Determinants of the prognosis after a first myocardial infarction in a migrant Japanese population : The Honolulu heart program. Circulation 1993 ; 88 : 2582-2595.
 
3) Steg PG, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes : Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004 ; 109 : 494-499.
PubMed
4) Forrester JS, et al. Medical therapy of acute myocardial infarction by application of hemodynamic subset. N Engl J Med 1976 ; 295 : 1356-1362.
PubMed
5) Rhodes A, et al. A randomized, controlled trial of the pulmonary artery catheter in critically ill patients. Intensive Care Med 2002 ; 28 : 256-264.
 
6) Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man) : A randomised controlled trial. Lancet 2005 ; 366 : 472.
 
7) Nohria A, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003 ; 41 : 1797-1804.
PubMed
P.29 掲載の参考文献
1) Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : The Task Force. Eur Heart J 2008 ; 29 : 2388-2442.
PubMed
2) Cotter G, et al. Acute heart failure : A novel approach to its pathogenesis and treatment. Eur J Heart Fail 2002 ; 4 : 227-234.
PubMed
3) Nohria A, et al. Medical management of advenced heart failure. JAMA 2002 ; 287 : 628-640.
 
4) Nohria A, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003 ; 41 : 1797-1804.
PubMed
5) Drazner MH, et al. Relationship between right and left-sided filling pressures in 1000 patients with acvanced heart failure. J Heart Lung Transplant 1999 ; 18 : 1126-1132.
PubMed
6) Mebazaa A, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008 ; 36 (Suppl) : S129-S139.
 
7) Gheorghiade M, et al. Acute heart failure syndromes. J Am Coll Cardiol 2009 ; 53 : 557-573.
PubMed
P.35 掲載の参考文献
1) Goto Y, et al. Effects of right ventricular ischemia on left ventricular geometry and the end-diastolic pressurevolume relationship in the dog. Circulation 1985 ; 72 : 1104-1114.
PubMed
2) 後藤葉一. 右室梗塞. 平盛勝彦ほか (編), 冠動脈疾患の集中治療. 東京 : 南江堂 ; 1988. pp. 115-122.
 
3) 後藤葉一. 拡張機能障害に対する治療法の考え方 (総論). Heart View 2001 ; 5 : 1598-1603.
 
4) 後藤葉一. 収縮能正常, 拡張能低下の心不全 (diastolic dysfunction). 心エコー2002 ; 3 : 156-165.
 
5) 後藤葉一. 拡張期心不全の頻度と臨床増. 循環器専門医 2003 ; 11 : 281-289.
 
P.40 掲載の参考文献
1) Ross J Jr. Afterload mismatch and preload reverse : A conceptual framework for the analysis of ventricular function. Prog Cardiovasc Dis 1976 ; 18 : 255-264.
 
2) Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989 ; 261 : 884-888.
PubMed
3) Nieminen MS, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure : The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005 ; 26 : 384-416.
 
P.49 掲載の参考文献
1) Jessup M, et al. 2009 focused update : ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009 ; 119 : 1977-2016.
 
2) Yamamoto K, et al. Determination of left ventricular filling pressure by Doppler echocardiography in patients with coronary artery disease : Critical role of left ventricular systolic function. J Am Coll Cardiol 1997 ; 30 : 1819-1826.
PubMed
3) Ommen SR, Nishimura RA. Clinical utility of doppler echocardiography and tissue doppler imaging in the estimation of left ventricular filling pressure ressures. Circulation 2000 ; 80 : 449-456.
 
4) Geske JB, et al. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy : Correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007 ; 116 : 2702-2708.
PubMed
5) Wilfried M, Allen G. Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure. Circulation 2009 ; 119 : 62-70.
 
P.55 掲載の参考文献
1) Forrester JS, et al. Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 1976 ; 295 : 1356-1362.
PubMed
2) Gorlin R, et al. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. Am Heart J 1951 ; 41 : 1.
PubMed
P.59 掲載の参考文献
1) Mebazaa A, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008 ; 36 (Suppl 1) : S129-S139.
 
2) Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009 ; 53 (7) : 557-573.
PubMed
3) Milne EN, et al. The radiologic distinction of cardiogenic and noncardiogenic edema. Am J Roentgenol 1985 ; 144 : 879-894.
 
P.64 掲載の参考文献
1) 諏訪邦夫. 血液ガスの臨床. 東京 : 中外医学社 ; 2006. pp. 4-5.
 
2) Martin L. 古賀俊彦 (訳). わかる血液ガス. 東京 : 秀潤社 ; 2006. pp. 207-214.
 

2章 心不全急性期の治療薬を使いこなす

P.69 掲載の参考文献
1) Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001 ; 96 : 132-143.
PubMed
2) Masip J, et al. Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary oedema : A randomized trial. Lancet 2000 ; 356 : 2126-2132.
PubMed
3) Bersten AD, et al. Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face mask. N Engl J Med 1991 ; 325 : 1825-1830.
 
P.75 掲載の参考文献
1) Filippatos G, Zannad F. An introduction to acute heart failure syndromes : Definition and classification. Heart Fail Rev 2007 ; 12 : 87-90.
PubMed
2) Gheorghiade M, et al. Acute heart failure syndromes : Current state and framework for future research. Circulation 2005 ; 112 : 3958-3968.
PubMed
3) Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008 ; 29 : 2388-2442.
 
4) Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001 ; 96 : 132-143.
PubMed
5) Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 ; 341 : 709-717.
 
6) Brown NJ. Eplerenone : Cardiovascular protection. Circulation 2003 ; 107 : 2512-2518.
PubMed
7) Konstam MA, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure : The EVEREST Outcome Trial. JAMA 2007 ; 297 : 1319-1331.
PubMed
・ Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009 ; 53 : 557-573.
PubMed
・ Izawa H, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy : A pilot study. Circulation 2005 ; 112 : 2940-2945.
PubMed
・ Harada K, et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure : Comparison with azosemide. J Cardiovasc Pharmacol 2009 ; 53 : 468-473.
PubMed
P.79 掲載の参考文献
1) Sharon A, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000 ; 36 : 832-837.
PubMed
2) Ignarro LJ, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide : Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981 ; 218 : 739-749.
PubMed
3) Cohn JN, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure : Results of a Veterans Administration cooperative study. N Engl J Med 1982 ; 306 : 1129-1135.
PubMed
4) Cotter G, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998 ; 351 : 389-393.
PubMed
P.83 掲載の参考文献
1) Cotter G, et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 2003 ; 5 : 443-451.
PubMed
P.88 掲載の参考文献
1) An account of the successful use of foxglove, in some dropsies, and in pulmonary consumption. In : Medical Transactions, Volume 3, 1785, published by the College of Physicians, London. Transaction XVI, pp. 255-286.
 
2) Liu L, et al. Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes. Am J Physiol Cell Physiol 2007 ; 293 (5) : C1489-1497.
PubMed
3) Liu J, et al. Ouabain interaction with cardiac Na+/K+-ATPase initiates signal cascades independent of changes in intracellular Na+ and Ca2+ concentrations. J Biol Chem 2000 ; 275 : 27838-27844.
PubMed
4) 柳沢輝行ほか (監訳). カッツング薬理学, 第9版. 東京 : 丸善 ; 2005. pp. 217-220.
 
5) Jessup M, et al. 2009 Focused Update : ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009 ; 119 : 1977-2016.
 
6) Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008 ; 29 : 2388-2442.
 
7) Packer M, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993 ; 329 (1) : 1-7.
PubMed
8) Uretsky BF, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure : Results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993 ; 22 (4) : 955-962.
 
9) The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997 ; 336 (8) : 525-533.
 
10) Rathore SS, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003 ; 289 (7) : 871-878.
PubMed
11) Gheorghiade M, et al. A neurohormonal modulator in heart failure? Circulation 1991 ; 84 (5) : 2181-2186.
PubMed
P.97 掲載の参考文献
1) Yoshizawa A, et al. Brain natriuretic peptide response is heterogeneous during β-blocker therapy for congestive heart failure. J Card Fail 2004 ; 10 : 310-315.
 
2) Fonarow GC, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure. J Am Coll Cardiol 2008 ; 52 : 190-199.
PubMed
3) Hernandez AF, et al. Clinical effectiveness of beta-blockers in heart failure. J Am Coll Cardiol 2009 ; 53 : 184-192.
PubMed
4) Bergstrom A, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Eur J Heart Fail 2004 ; 6 : 453-461.
PubMed
5) van Veldhuissen DJ, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol 2009 ; 53 : 2150-2158.
PubMed
6) Kataoka M, et al. Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure. Circ J 2008 ; 72 : 358-363.
PubMed
7) Tamura A, et al. Relationship between β-blocker treatment and the severity of central sleep apnea in chronic heart failure. Chest 2007 ; 131 : 130-135.
 
・ Metra M, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. J Am Coll Cardiol 2002 ; 40 : 1248-1258.
PubMed
・ Maack C, et al. Characterization of β1-selectivity, adrenoceptor-Gs-protein interaction and inverse agonism of nebivolol in human myocardium. Br J Pharmacol 2001 ; 132 : 1817-1826.
 
・ Davis ME, et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006 ; 113 : 977-985.
PubMed
・ Liggett SB, et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci USA 2006 ; 103 : 11288-11293.
 
・ Nagatomo Y, et al. A pilot study on the role of autoantibody targeting the β1-adrenergic receptor in the response to β-blocker therapy for congestive heart failure. J Card Fail 2009 ; 15 : 224-232.
 
P.103 掲載の参考文献
1) Kangawa K, et al. Purification and complete amino acid sequence of α-human atrial natriuretic properties. Biochem Biophys Res Commun 1984 ; 118 : 131.
 
2) De Bold AJ, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981 ; 28 : 89.
PubMed
3) Saito Y, et al. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure : Beneficial effects on left ventricular function. Circulation 1987 ; 76 (1) : 115-124.
PubMed
4) Nomura F, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure : COMPASS : Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ J 2008 ; 72 : 1777-1786.
PubMed
5) Kitakaze M, et al. J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND). Lancet 2007 ; 370 : 1483-1493.
PubMed
6) Chen HH, et al. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary bypass surgery : A double blind placebocontrolled pilot study. Circulation 2007 ; 116 (Suppl 11) : I134.
 
7) Shono M, et al. Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J 2007 ; 71 : 1040-1046.
PubMed
P.110 掲載の参考文献
1) Packer M, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med 1996 ; 334 : 1349-1355.
 
2) Hori M, et al. MUCHA Investigators : Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure : The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004 ; 147 : 324-330.
PubMed
3) Kawashiro N, et al. Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure. J Cardiol 2006 ; 47 : 229-237.
PubMed
4) 清野精彦. 急性心不全の病態と内科的治療. 進歩する心臓研究 1994 ; 24 : 37-45.
 
5) Follath F, et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study : Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) : A randomised double-blind trial. Lancet 2002 ; 360 : 196-202.
 
6) Felker GM, et al. OPTIME-CHF Investigators : Heart failure etiology and response to milrinone in decompensated heart failure, results from the OPTIMA-CHF study. J Am Coll Cardiol 2003 ; 41 : 997-1003.
 
7) Watanabe H, et al. Combination therapy with PDE III inhibitor for heart failure. Nippon Rinsho 2007 ; 65 (Suppl 5) : 134-139.
 
8) 梶本克也ほか. 強心剤のコントラバーシ : 急性心不全に強心剤を使うべき. 呼吸と循環 2004 ; 52 : 897-902.
 
9) Cuffe MS, et al. for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure : A randomized controlled trial. JAMA 2002 ; 287 : 1541-1547.
PubMed
10) Watanabe H, et al. Acute efficacy of combined PDE III-inhibitor and low-dose dobutamine therapy in patients with acute exacerbation of chronic heart failure receiving beta-blocker. J Cardiol Jpn Ed 2008 ; 1 : 148-154.
 
11) Gage J, et al. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 1986 ; 74 : 367-373.
PubMed
12) Jhaveri R, et al. Enhanced vasodilatory responses to milrinone in catecholamine-precontracted small pulmonary arteries. Anesth Analg 2004 ; 98 : 1618-1622.
PubMed
P.122 掲載の参考文献
1) 心房細動治療 (薬物) ガイドライン (2008 年改訂版). Circ J 2008 ; 72 (Suppl IV) : 1581-1638.
 
2) 志賀剛. アミオダロンの臨床使用と注意点. 不整脈にアミオダロンをどう使うか. 日本心電学会学術諮問委員会 (編), 循環器薬物治療実践シリーズI, 新不整脈学. 東京 : ライフメディコム ; 2002. pp. 25-41.
 
3) 栗田隆志ほか. アミオダロン療法の新しい展開 適応不整脈以外の新しい使用法の可能性を求めて. 日本心電学会学術諮問委員会 (編), 循環器薬物治療実践シリーズ I, 新不整脈学. 東京 : ライフメディコム ; 2002. pp. 25-41.
 
4) Takenaka K, et al. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Jpn Circulation J 2001 ; 65 : 60-62.
 
5) 栗田隆志. 静注 III 群薬を使うとき-適応と使いかた. Medical Practice 2006 ; 23 : 847-854.
Medical*Online
6) Katoh T, et al. Efficacy and safety of intravenous amiodarone infusion in Japanese patients with hemodynamically compromised ventricular tachycardia or ventricular fibrillation. J Arrhythmia 2007 ; 23 : 131-139.
 
P.128 掲載の参考文献
1) Opie LH (編著). 岩瀬三紀, 横田充弘 (監訳). オピーの心臓生理学 細胞から循環まで. 東京 : 西村書店 ; 2008. pp. 134-152.
 
2) O'Connor CM, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure : Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999 ; 138 : 78-86.
PubMed
P.134 掲載の参考文献
1) 『急性心不全治療ガイドライン (2006年改訂版) 』<JCS 2006>.
 
2) Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology ; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008 ; 29 (19) : 2388-2442.
 
3) European Society of Cardiology ; Heart Failure Association of the ESC (HFA) ; European Society of Intensive Care Medicine (ESICM). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008 ; 10 (10) : 933-989.
 
4) Gheorghide M, et al. Acute heart failure syndromes. J Am Call Cardiol 2009 ; 53 (7) : 557-573.
 
P.137 掲載の参考文献
1) Bergman MR, et al. Myocardial tumor necrosis factoralpha secretion in hypertensive and heart failure-prone rats. Am J Physiol 1999 ; 277 : H543-H550.
PubMed
2) Takeuchi K, et al. Vesnarinone and amrinone reduce the systemic inflammatory response syndrome. J Thorac Cardiovasc Surg 1999 ; 117 : 375-382.
PubMed
3) Mikawa K, et al. The effect of phosphodiesterase III inhibitors on human neutrophil function. Crit Care Med 2000 ; 28 : 1001-1005.
PubMed
4) Sanada S, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors : The role of protein kinase A and p38 mitogen-activated protein kinase. Circulation 2001 ; 104 : 705-710.
PubMed
5) Lopez-Candales A, et al. Symptomatic improvement in patients treated with intermittent infusion of inotropes : A double-blind placebo controled pilot study. J Med 2002 ; 33 : 129-146.
PubMed
6) Sanada S, et al. Role of phasic dynamism of p38 mitogenactivated protein kinase activation in ischemic preconditioning of the canine heart. Circ Res 2001 ; 88 : 175-180.
PubMed
7) Hayashi M, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001 ; 37 : 1820-1826.
PubMed
8) Kitakaze M, and J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (JWIND) : Two randomised trials. Lancet 2007 ; 370 : 1483-1493.
 
9) Tanaka T, et al. Effect of atrial natriuretic peptide on adiponectin in patients with heart failure. Eur J Heart Fail 2008 ; 10 : 360-366.
PubMed
10) Tsukamoto O, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009 ; 53 : 2070-2077.
PubMed
11) Asanuma H, Kitakaze M. Carperitide and adiponectin : How are they connected each other to benefit acute decompensated heart failure? Circ J 2009 ; 73 : 2206-2207.
PubMed
12) Kitakaze M, et al. Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts : Role of bradykinin and nitric oxide. Hypertens Res 2000 ; 23 : 253-259.
PubMed
13) Asanuma H, et al. Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. Circulation 2004 ; 109 : 2773-2779.
PubMed
14) Asanuma H, et al. Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release. J Cardiovasc Pharmacol 2003 ; 41 : 499-505.
PubMed
15) Liao Y, et al. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 2004 ; 110 : 692-699.
PubMed
16) Kitakaze M, et al. Adenosine and cardioprotection in the diseased heart. Jpn Circ J 1999 ; 63 : 231-243.
PubMed

3章 心不全急性期の非薬物療法に親しむ

P.144 掲載の参考文献
1) Barish R, Naradzay J. Approach to Cardiovascular Emergencies. In : Goldman L, Braumwald E (editors), Primary Cardiology, 2nd edition. Philadelphia : Saunders ; 2003. p. 363.
 
2) Peter JV, et al. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema : A meta-analysis. Lancet 2006 ; 367 : 1155-1163.
PubMed
3) Bradley TD, et al. Cardiac output response to continuous positive airway pressure in congestive heart failure. Am Rev Respir Dis 1992 ; 145 : 377-382.
PubMed
4) Nohria A, et al. Medical management of advanced heart failure. JAMA 2002 ; 287 : 628-640.
PubMed
5) Mebazaa A, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008 ; 36 (Suppl 1) : S129-139.
 
P.151 掲載の参考文献
1) Wilkoff BL, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defi brillator : The Dual Chamber and VVI Implantable Defi brillator (DAVID) Trial. JAMA 2002 ; 288 : 3115-3123.
 
2) Lamas GA, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002 ; 346 : 1854-1862.
 
3) Sweeney MO, et al. Search AV extension and managed ventricular pacing for promoting atrioventricular conduction (SAVE PACe) trial. Minimizing ventricular pacing to reduce atrial fi brillation in sinus-node disease. N Engl J Med 2007 ; 357 : 1000-1008.
 
4) Williamson BD, et al. Radiofrequency catheter modifi cation of atrioventricular conduction to control the ventricular rate during atrial fi brillation. N Engl J Med 1994 ; 331 : 910-917.
 
5) Wood MA, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation : A meta-analysis. Circulation 2000 ; 101 : 1138-1144.
PubMed
P.160 掲載の参考文献
1) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996 ; 335 : 1933-1940.
 
2) Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237.
 
3) Moss AJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.
PubMed
4) Chung ES, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008 ; 117 : 2608-2616.
PubMed
5) Cleland JG, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005 ; 352 : 1539-1549.
PubMed
6) Konstantino Y, et al. Urgent cardiac resynchronization therapy in patients with decompensated chronic heart failure receiving inotropic therapy. A case series. Cardiology 2006 ; 106 : 59-62.
PubMed
7) Bristow MR, et al. Cardiac resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 ; 350 : 2140-2150.
 
P.168 掲載の参考文献
1) Santa-Cruz RA, et al. Aortic counterpulsation : A review of the hemodynamic effects and indications for use. Catheter Cardiovasc Interv 2006 ; 67 (1) : 68-77.
PubMed
2) Trost JC, Hillis LD. Intra-aortic balloon counterpulsation. Am J Cardiol 2006 ; 97 (9) : 1391-1398.
PubMed
3) 松田暉ほか. 経皮的心肺補助法. PCPS の基礎から臨床まで. 東京 : 秀潤社 ; 2001. p. 87.
 
P.175 掲載の参考文献
1) 日本人工臓器学会. 補助人工心臓. 人工臓器 2006 ; 35 (別冊) : 55-58.
 
2) 中谷武嗣ほか. 人工心臓と心臓移植. 循環器専門医 2001 ; 9 : 51-56.
 
3) Nakatani T, et al. Recovery of cardiac function by long-term left ventricular support in patients with end-stage cardiomyopathy. ASAIO Journal 1998 ; 44 : M516-M520.
PubMed
4) Rose EA, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001 ; 345 : 1435-1443.
PubMed
5) 許俊鋭 (編). 補助循環マスターポイント102, 改訂2版. 東京 : メジカルビュー社 ; 2009.
 
6) Chumnanvej S, et al. Perioperative echocardiographic examination for ventricular assist device implantation. Anesth Analg 2007 ; 105 (3) : 583-601.
PubMed
7) Frogel J, et al. Transesophageal echocardiography diagnosis of extracardiac left ventricular assist device inflow cannula obstruction in a patient with thoratec intracorporeal ventricular assist device biventricular support. Am Soc Echocardiogr 2008 ; 21 (6) : 777. e5-6.
 
8) Gojo S, et al. Successful LVAS and RVAS-ECMO support in a patient with fulminant myocarditis who failed to recover from ventricular fibrillation with PCPS and IABP. J Thorac Cardivasc Surg 2003 ; 126 (3) : 885-886.
 
P.185 掲載の参考文献
1) Lund O, Bland M. Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement. J Thorac Cardiovasc Surg 2006 ; 132 : 20-26.
PubMed
2) Cohn LH, et al. Twenty-year follow-up of the Hancock modified orifice porcine aortic valve. Ann Thorac Surg 1998 ; 66 (Suppl) : S30-S34.
 
3) Banbury MK, et al. Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg 2001 ; 72 : 753-757.
 
4) Vinod H, et al. Outcomes and long-term survival for patients undergoing mitral valve repair versus replacement effect of age and concomitant coronary artery bypass grafting. Circulation 2003 ; 108 : 298-304.
 
P.193 掲載の参考文献
1) Komeda M, et al. Surgical repair of postinfarction ventricular septal defect. Circulation 1990 ; 82 (Suppl 5) : IV24-37.
 
2) Terashima M, et al. Outcome of percutaneous intrapericardial fi brin-glue injection therapy for left ventricular free wall rupture secondary to acute myocardial infarction. Am J Cardiol 2008 ; 101 (4) : 419-421.
 
3) Muto A, et al. Sutureless repair with TachoComb sheets for oozing type postinfarction cardiac rupture. Ann Thorac Surg 2005 ; 79 (6) : 2143-2145.
PubMed
4) Nishina T, et al. Two cases using "epi-endocardial patch repair" for postinfarction left ventricular rupture. J Card Surg 2003 ; 18 (2) : 164-166.
PubMed
P.201 掲載の参考文献
1) Taylor DO. et al. Registry of the International Society for Heart and Lung Transplantation : Twenty-sixth official adult heart transplantation-2009. J Heart Lung Transplant 2009 ; 28 : 989-1049.
 
2) Nakatani T. Heart transplantation. Circ J 2009 ; Suppl A : A55-A60.
 
3) 日本心臓移植研究会. 本邦心臓移植登録報告 (2009年). 移植 2009 ; 44 : 572-575.
Medical*Online
P.207 掲載の参考文献
1) Brater DC, et al. Bumetanide and furosemide in heart failure. Kidney Int 1984 ; 26 : 183-189.
PubMed
2) Cotter G, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 1997 ; 62 : 187-193.
PubMed
3) Hasselblad V, et al. Relation between dose of loop diuretics and outcomes in a heart failure population : Results of the ESCAPE trial. Eur J Heart Fail 2007 ; 9 : 1064-1069.
 
4) Bart BA, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure : The Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005 ; 46 : 2043-2046.
 
5) Costanzo MR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007 ; 49 : 675-683.
PubMed
6) Libetta C, et al. Intermittent haemodiafiltration in refractory congestive heart failure : BNP and balance of inflammatory cytokines. Nephrol Dial Transplant 2007 ; 22 : 2013-2019.
PubMed

4章 心不全の原因疾患と急性期対応を知る

P.216 掲載の参考文献
1) 急性心筋梗塞 (ST 上昇型) の診療に関するガイドライン <JCS 2008>. Circ J 2008 ; 72 (Suppl IV) : 1348-1442.
 
2) Forrester JS, et al. Medical therapy of acute myocardial infarction by application of hemodynamic subset. N Engl J Med 1976 ; 295 : 1356-1362.
PubMed
P.223 掲載の参考文献
1) Killip T 3rd, et al. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967 ; 20 : 457-464.
 
2) Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008 ; 29 : 2388-2442.
 
3) Nohria A, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003 ; 41 : 1797-1804.
PubMed
4) 竹田晋浩. NPPVによる呼吸管理の治療と予後. ICUとCCU 2007 ; 31 (11) : 843-847.
Medical*Online
5) 日本呼吸器病学会NPPV ガイドライン作成委員会. 日本呼吸器病学会Noninvasive Positive Pressure Ventilation (NPPV) ガイドライン. 日呼吸会誌 2006 ; 44 (6) : 479-484.
 
6) Forrester JS, et al. Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 1976 ; 295 (24) : 1356-1362.
PubMed
7) 鈴木利保. 非心臓手術におけるCCO (連続心拍出量) 測定の意義と有用性. Anet anesthesia network 2006 ; 10 (1).
 
8) Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report : Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989 ; 321 : 406-412.
 
9) Dor V, et al. Late hemodynamic results after left ventricular patch repair associated with coronary grafting in patients with postinfarction akinetic or dyskinetic aneurysm of the left ventricle. J Thorac Cardiovasc Surg 1995 ; 110 : 1291-1301.
 
10) Kihara T, et al. Waon therapy improves the prognosis of patients with chronic heart failure. J Cardiol 2009 ; 53 : 214-218.
PubMed
11) Mebazaa A, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008 ; 36 (Suppl 1) : S129-139.
 
P.230 掲載の参考文献
1) Levy D, et al. The progression from hypertension to congestive heart failure. JAMA 1996 ; 275 : 1557-1562.
PubMed
2) Ganau A, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992 ; 19 : 1550-1558.
 
3) Levy D, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990 ; 322 : 1561-1566.
PubMed
4) Lenzen MJ, et al. Differences between patients with a preserved and a depressed left ventricular function : A report from the EuroHeart Failure Survey. Eur Heart J 2004 ; 25 : 1214-1220.
 
5) Paulus WJ, et al. How to diagnose diastolic heart failure : A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007 ; 28 : 2539-2550.
 
6) Yamaguchi H, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004 ; 43 : 55-60.
PubMed
7) Piccini JP, et al. New insights into diastolic heart failure : Role of diabetes mellitus. Am J Med 2004 ; 116 (Suppl 5A) : 64S-75S.
 
P.239 掲載の参考文献
1) 北畠顕, 友池仁暢 (編). 心筋症 : 診断の手引きとその解説. 厚生労働省難治性疾患克服研究事業 特発性心筋症調査研究班. 札幌 : かりん社 ; 2005. pp. 37-50.
 
2) Hunt SA, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guideline for the Diagnosis and Management of Heart Failure in Adults : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines : Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009 ; 119 ; e391-e479.
 
3) Barry J, et al. Contemporary definitions and classification of the cardiomyopathies : An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee ; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups ; And Council on Epidemiology and Prevention. Circulation 2006 ; 113 ; 1807-1816.
 
4) ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2005 ; 112 (Suppl 24) : IV1-203.
 
5) Richardson P, et al. Report of the 1995 World Health Organization/Internal Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996 ; 93 : 841-842.
 
6) Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 2005 ; 96 : 144-147.
PubMed
7) Matsumori A. Global alert and response network for hepatitis C virus-derived heart diseases : A call to action. CVD Prevention and Control 2009 ; 4 : 109-118.
 
8) Miura K, et al. Prognosis and prognostic factors in patients with idiopathic dilated cardiomyopathy in Japan results from a Nationwide Study. Circ J 2008 ; 72 : 343-348.
PubMed
P.246 掲載の参考文献
1) Aurigemma GP, et al. Impact of chamber geometry and gender on left ventricular systolic function in patients > 60 years of age with aortic stenosis. Am J Cardiol 1994 ; 74 : 794-798.
PubMed
2) Monin JL, et al. Low-gradient aortic stenosis. Operative risk stratification and predictors for long-term outcome : A multicenter study using dobutamine stress hemodynamics. Circulation 2003 ; 108 : 319-324.
PubMed
3) Khot UN, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003 ; 348 : 1756-1763.
PubMed
4) Webb JG, et al. Transcatheter aortic valve implantation : Impact on clinical and valve-related outcomes. Circulation 2009 ; 119 : 3009-3016.
PubMed
5) Bergler-Klein J, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004 ; 109 : 2302-2308.
PubMed
6) Tribouilloy C, et al. Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J Am Coll Cardiol 2009 ; 53 : 1865-1873.
PubMed
7) Herman D, et al. Transesophageal echocardiographic description of the mechanisms of aortic regurgitation in acute type A aortic dissection : Implications for aortic valve repair. J Am Coll Cardiol 2000 ; 36 : 884-890.
 
8) Feldman BJ, et al. Incidence, description and functional assessment of isolated quadricuspid aortic valves. Am J Cardiol 1990 ; 65 : 937-938.
PubMed
P.252 掲載の参考文献
1) 吉田清. チャートでわかる実践心エコー図法, 第2版. 東京 : 南江堂 ; 2009.
 
2) 林田晃寛, 吉田清. 私はこう考える「虚血性僧帽弁逆流 : 外科手術の適応は? 」. J Cardiol Jpn Ed 2009 ; 4 : 146-152.
 
3) 林田晃寛, 吉田清. 虚血性僧帽弁閉鎖不全症に対する治療戦略. 山口徹ほか (編), Annual Review循環器 2008. 東京 : 中外医学社 ; 2008. pp. 258-266.
 
P.259 掲載の参考文献
1) Oh JK, et al (editors). Doppler echocardiography and color flow imaging : Comprehensive noninvasive hemodynamic assessment. In : The Echo Manual, 3rd edition. Philadelphia : Lippincott Williams & Wilkins ; 2006. pp. 59-79.
 
2) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) : Developed in collaboration with the Society of Cardiovascular Anesthesiologists : Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006 ; 114 (5) : e84-231.
 
P.267 掲載の参考文献
1) Frommer P, et al. Paired electrical stimulation. Comparison of the eff ects on performance of the failing and nonfailing heart. Am J Cardiol 1966 ; 18 : 738-744.
 
2) 橋場邦武. 老年者の不整脈. 日老医誌 1989 ; 26 : 101-109.
 
3) Harris A, et al. A etiology of chronic heart block. A clinico-pathological correlation in 65 cases. Br Heart J 1969 ; 31 (2) : 206-218.
 
4) Sweeney MO, Hellkamp AS. Heart failure during cardiac pacing. Circulation (United States) 2006 ; 113 (17) : 2082-2088.
PubMed
P.273 掲載の参考文献
1) Umana E, et al. Tachycardia-induced cardiomyopathy. Am J Med 2003 ; 114 : 51-55.
PubMed
2) Shinbane JS, et al. Tachycardia-induced cardiomyopathy : A review of animal models and clinical studies. J Am Coll Cardiol 1997 ; 29 : 709-715.
PubMed
3) Pak PH, et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol 1997 ; 30 : 576-584.
PubMed
4) Takemoto M, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 2005 ; 45 : 1259-1265.
 
5) Fenelon G, et al. Tachycardiomyopathy : Mechanisms and clinical implications. Pacing Clin Electrophysiol 1996 ; 19 : 95-106.
 
6) Jeong YH, et al. Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 2008 ; 31 : 172-178.
PubMed
7) Hunt SA, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults : A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009 ; 119 : e391-479.
 
8) Hsu LF, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004 ; 351 : 2373-2383.
PubMed
9) Nerheim P, et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004 ; 110 : 247-252.
PubMed
10) Ilkhanoff L, et al. Changes in ventricular dimensions and function during recovery of atrial tachycardia-induced cardiomyopathy treated with catheter ablation. J Cardiovasc Electrophysiol 2007 ; 18 : 1104-1106.
PubMed
P.275 掲載の参考文献
1) Khan SS, et al. Managed care interventions for improving outcomes in acute heart failure syndromes. Am J Manag Care 2008 ; 14 (Suppl) : S273-286.
 
2) 西清人ほか. 末期慢性心不全患者に対する外来点滴治療. J Cardiol 2007 ; 49 : 251-258.
 
3) Anker SD, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997 ; 349 : 1050-1053.
PubMed

書評

最近チェックした商品履歴

Loading...